Abstracts tagged "juvenile idiopathic arthritis (JIA) and registries"

Abstract Number: 2866 • 2018 ACR/ARHP Annual Meeting
Biologic Refractory Disease in a Cohort Study of Children and Young People with Juvenile Idiopathic Arthritis from the United Kingdom
Eleanor Heaf¹, Lianne Kearsley-Fleet¹, Rebecca Davies¹, Diederik De Cock², Eileen Baildam³, Michael W. Beresford^3,4, Helen E. Foster⁵, Taunton R. Southwood⁶, Wendy Thomson^7,8 and Kimme L. Hyrich^2,8, ¹Arthritis Research UK Centre for Epidemiology, The University of Manchester, Manchester Academic Health Science Centre, Manchester, United Kingdom, ²Arthritis Research UK Centre for Epidemiology, The University of Manchester, Manchester, United Kingdom, ³Clinical Academic Department of Paediatric Rheumatology, Alder Hey Children's NHS Foundation Trust, Liverpool, United Kingdom, ⁴Institute of Translational Medicine (Child Health), University of Liverpool, Liverpool, United Kingdom, ⁵Newcastle University and Great North Children's Hospital, Newcastle Upon Tyne, United Kingdom, ⁶Institute of Child Health, University of Birmingham and Birmingham Children's Hospital, Birmingham, United Kingdom, ⁷Arthritis Research UK Centre for Genetics and Genomics, The University of Manchester, Manchester Academic Health Science Centre, Manchester, United Kingdom, ⁸National Institute of Health Research Manchester Biomedical Research Centre, Manchester University NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, United Kingdom
Background/Purpose: Biologics are a main treatment option for children and young people with juvenile idiopathic arthritis (JIA) who do not respond or are intolerant to…
Abstract Number: 282 • 2014 ACR/ARHP Annual Meeting
Pharmacovigilance in Juvenile Idiopathic Arthritis Patients (PHARMACHILD) Treated with Biologic Agents and/or Methotrexate. Consolidated Baseline Characteristics from Pharmachild and Other National Registries
Joost F. Swart¹, Alessandro Consolaro², Gerd Horneff³, Kimme L. Hyrich⁴, Francesca Bovis⁵, Bo Magnusson⁶, Jose Melo-Gomes⁷, Ekaterina Alexeeva⁸, Stefano Lanni⁹, Gerd Ganser¹⁰, Violeta Vladislava Panaviene¹¹, Jordi Anton¹², Ivan Foeldvari¹³, Valda Stanevicha¹⁴, Susan Nielsen¹⁵, Ralf Trauzeddel¹⁶, Constantin Ailioaie¹⁷, Pierre Quartier¹⁸, Toni Hospach¹⁹, Gordana Susic²⁰, Maria Trachana²¹, Frank Weller-Heinemann²², Alberto Martini²³, Nico Wulffraat²⁴ and Nicolino Ruperto²⁵, ¹Pediatric Rheumatology, Wilhelmina Children's Hospital/ UMC Utrecht, Utrecht, Netherlands, ²Pediatria II, Istituto Giannina Gaslini, Genova, Italy, ³Asklepios Klinik Sankt Augustin, Sankt Augustin, Germany, ⁴Centre for Musculoskeletal Research, University of Manchester, Manchester, United Kingdom, ⁵Pediatria II, PRINTO, PRINTO - Istituto Giannina Gaslini, Genoa, Italy, ⁶Pediatric Rheumatology, Karolinska University Hospital, Stockholm, Sweden, ⁷Pediatric Rheumatology, Lisbon, Portugal, ⁸Scientific Centre of Children’s Health of RAMS, Moscow, Russia, ⁹Pediatria II, Istituto Giannina Gaslini, Genoa, Italy, ¹⁰Pediatric Rheumatology, Sankt Josef Stift, Sendenhorst, Germany, ¹¹Children‘s Hospital, Affiliate of Vilnius University Hospital Santariskiu Klinikos, Vilnius, Lithuania, ¹²Hospital Sant Joan de Déu, Barcelona, Spain, ¹³Department of Pediatric Rheumatology, Hamburger Zentrum für Kinder und Jugendrheumatologie, Hamburg, Germany, ¹⁴Department of Paediatrics, Riga Stradins University, Riga, Latvia, ¹⁵University Clinic of Pediatrics II, Rigshospitalet, Copenhagen, Denmark, ¹⁶Pediatrics, Helios Clinics, Berlin, Germany, ¹⁷Department of Medical Physics, Alexandru Ioan Cuza University, Iasi, Romania, ¹⁸Necker-Enfants Malades Hospital, Paris, France, ¹⁹Pediatric Rheumatology, Olgahospital, Stuttgart, Germany, ²⁰Institute of Rheumatology, School of Medicine, University of Belgrade, Belgrade, Serbia, ²¹Aristotle University, Thessaloniki, Greece, ²²Klinikum Bremen-Mitte, Bremen, Germany, ²³PRINTO-IRCCS, Genova, Italy, ²⁴Pediatric rheumatology, Wilhelmina Children's Hospital/ UMC Utrecht, Utrecht, Netherlands, ²⁵Pediatria II,, Istituto Giannina Gaslini, Genoa, Italy
Background/Purpose The availability of methotrexate (MTX) and biological agents has provided a major change in the treatment of children with juvenile idiopathic arthritis (JIA). However,…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].